Journal
SEMINARS IN ONCOLOGY
Volume 41, Issue 1, Pages 126-132Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminoncol.2013.12.014
Keywords
-
Categories
Funding
- NCI NIH HHS [U10 CA180802, P30 CA006973] Funding Source: Medline
Ask authors/readers for more resources
Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available